{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-130564","form_type":"8-K","ticker":"ALEC","cik":"0001653087","company_name":"Alector, Inc.","filed_at":"2024-11-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.117114+00:00","generated_at":"2026-05-29T18:54:36.696703+00:00","sec_items":["2.05","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Alector AL002 Phase 2 fails primary endpoint; cuts workforce 17%","bullets":["AL002 did not slow Alzheimer's progression on CDR-SB; no benefit on secondary endpoints or biomarkers.","Stopping long-term extension of INVOKE-2 study; reducing workforce by ~41 employees (17% of staff).","Restructuring charges estimated at $3.9 million, primarily severance and benefits, to be paid by H1 2025.","Cash and investments of $457.2M as of Sep 30, 2024 expected to fund operations through 2026.","Topline data for latozinemab Phase 3 in FTD-GRN expected late 2025/early 2026; AL101/GSK4527226 Phase 2 enrollment over one-third."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-130564","json":"https://secwatch.observer/filing/0000950170-24-130564.json","markdown":"https://secwatch.observer/filing/0000950170-24-130564.md","text":"https://secwatch.observer/filing/0000950170-24-130564.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1653087/000095017024130564/0000950170-24-130564-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1653087/000095017024130564/alec-20241125.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T18:54:36.696703+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a1fa576a252dedaa56651c8cfbcc314ea0319b34","claim":"Alector, Inc. announced a restructuring with charges of approximately $3.9 million (approximately 41 employees).","evidence_excerpt":"On November 25, 2024, Alector, Inc. (“Alector” or “the Company”) committed to a plan to reduce its workforce (the “Plan”) by approximately 17% in order to align resources with the Company's strategic priorities. Based upon the results of the Company's INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in early Alzheimer’s disease, the Company is stopping the long term extension of the INVOKE-2 study. The Company initiated a reduction in force impacting approximately 41 employees across the organization. The Company continues to expect that its existing cash, cash equivalents and investments will enable it to fund its operating expenses and capital expenditure requirements through 2026. One-time restructuring charges associated with the reduction in force are expected to be approximately $3.9 million, primarily consisting of personnel expenses such as salaries, one-time severance payments, and other benefits.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1653087/000095017024130564/0000950170-24-130564-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $3.9 million"},{"label":"Headcount","value":"approximately 41 employees"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}